Compare Globus Medical Inc. Class A Common Stock (GMED) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Las Vegas Sands Corp. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Las Vegas Sands Corp. trades at $37.07 (market cap $23.99B). The key difference: Las Vegas Sands Corp. is far larger — about 2.3× Globus Medical Inc. Class A Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Las Vegas Sands Corp. for 73 Days on average.
| GMED | LVS | |
|---|---|---|
Market Cap | $10.25B | $23.99B |
Volume | 1,108,124 | 5,076,550 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $69.49 |
52-Week Low | $58.33 | $35.81 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $9.76B | $35.88B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
LVS trades at $37.02, up 2.41% today, but faces bearish technical signals with strong selling pressure on moving averages. The company shows solid fundamentals with revenue growth from $13.02B in 2025 to projected $13.7B in 2026, net margins around 12.5%, and attractive valuation with P/E of 14.36. Recent earnings show mixed results with Q2 2026 missing expectations after two consecutive beats. Analysts maintain strong buy consensus with $58.89 price target representing 59% upside potential.
LVS presents compelling value with strong analyst support and reasonable valuations, though technical weakness and high debt levels pose near-term risks. The company's consistent revenue growth and Macao recovery provide upside catalysts, but investors should monitor debt management and gaming regulatory environment. The significant gap between current price and analyst targets suggests substantial potential reward for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
